Piroxicam after lower third molar surgery for postoperative pain

Primary tabs

Piroxicam after lower third molar surgery for postoperative pain

Nonsteroidal anti-inflammatory drugs (NSAIDs) are metabolized by the cytochrome P450 enzymes (CYPs), predominantly CYP2C8 and CYP2C9.

The presnt study by Calvo A M and colleagues assessed the possible association between polymorphisms in the CYP2C8*3 and CYP2C9 genes with the therapeutic effect of oral piroxicam (20 mg daily for 4 days) after lower third molar surgeries with regard to postoperative pain, swelling, trismus, adverse reactions, need for rescue medication and the volunteer’s overall satisfaction.

To achieve this CYP2C8*3 and CYP2C9 polymorphisms on genotyped 102 volunteers and genomic DNA was isolated from collected saliva subjected to invasive lower third molar surgeries, and the data collected and analyzed from preoperative, intraoperative and postoperative parameters. An equal amount of piroxicam sufficiently managed postoperative pain and inflammatory symptoms, with visual analog pain scores typically <40 mm for all genotypes investigated resulted. Only 2 out of 102 volunteers heterozygous for CYP2C8*3 and CYP2C9*3 reported adverse side effects. In general, slow metabolizers of piroxicam, who were volunteers with mutant alleles, were indifferent from normal metabolizers with the wild-type alleles and therefore, did not require specialized piroxicam doses to manage the postoperative pain and inflammation.


Journal of Pain Research 2017, 10:1581-1589

Link to the source:


Original title of article:

Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C8*3 and CYP2C9


Adriana Maria Calvo et al.

Therapeutic, Piroxicam, Pain, NSAIDs, RCT, Efficacy, Visual analog pain scores
Log in or register to post comments